Cost Effective Analysis of Inhalers Used for Asthma Management: An Interventional Approach

Objective: To evaluate the cost-effectiveness of corticosteroid inhalers, patient counseling, and factors influencing prescribing patterns and medication adherence. Methods: Prospective interventional sampling approach included patients aged 18-60 with asthma, excluding pregnant/lactating women, unwilling patients, and those with communication problems. Patients received counseling on inhaler use. Results: Asthma incidence peaked in patients aged 48+ (30.6%).Upper-middle-class patients predominated (59%). Counseling improved adherence (76.4%). Patient satisfaction was high (47.2%). Pulmonary function test (PFT) values improved post-adherence (84.118±12.647). Fluticasone/Formoterol was the most common inhaler (41.7%). Budesonide/Formoterol had the lowest mean drug cost (Rupees 476.095±119.717). Total cost analysis revealed Fluticasone/Formoterol as most cost-effective (Rupees 5464.547 ± 1015.616). Proper adherence reduced drug costs (Rupees 544.042±398.614 vs. 1154.499 ± 369.435). Conclusion: Fluticasone/Formoterol was the most cost-effective corticosteroid inhaler. Direct patient/caregiver interaction and counseling significantly improved asthma control, medication adherence, and patient satisfaction. Using clear language and visual aids enhanced comprehension.